HRS-9821 / Jiangsu Hengrui Pharma, GSK - LARVOL DELTA

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology (PRNewswire) - "Hengrui Pharma...announced it has entered into agreements with GSK...to develop up to 12 innovative medicines, adding significant value to the globalization strategy of Hengrui and significant new growth opportunities to GSK beyond 2031....GSK will pay $500 million in upfront fees across the agreements. The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong SAR, Macau SAR and Taiwan region) for a potential best-in-class, PDE3/4 inhibitor (HRS-9821) in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, irrespective of background therapy....The agreements also include a pioneering scaled collaboration to generate up to 11 programmes in addition to HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programmes up to completion of phase I trials, including patients outside of China."

Licensing / partnership • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Oncology

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients (clinicaltrials.gov) - P1 | N=106 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Trial completion date: Sep 2025 ➔ Jun 2025 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Jiangsu Hengrui Pharmaceuticals Gains Approval for Clinical Trial of New Inhalation Drug (TipRanks) - "Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals, has received approval from the National Medical Products Administration for a clinical trial of its HRS-9821 inhalation powder. This approval marks a significant step for the company as it aims to advance its product pipeline in treating chronic obstructive pulmonary conditions, potentially strengthening its position in the pharmaceutical market."

New trial • Chronic Obstructive Pulmonary Disease

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients (clinicaltrials.gov) - P1 | N=106 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects (clinicaltrials.gov) - P1 | N=134 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | N=80 ➔ 134 | Trial completion date: Sep 2023 ➔ Sep 2025 | Trial primary completion date: Jul 2023 ➔ Jul 2025

Enrollment change • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases